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Abstract Sterols, and specifically oxysterols, play important
roles in the biosynthesis of bile acids and steroid hormones as
well as possessing biological activities in their own right.
Analysis of oxysterols is complicated due to their low abun-
dance in biological systems and poor ionisation characteristics
in mass spectrometry. Over the past decade, we have devel-
oped a liquid chromatography–mass spectrometry method
termed enzyme-assisted derivatisation for sterol analysis
(EADSA). Our derivatisation procedure relies on two solid-
phase extraction steps to (i) separate cholesterol from
oxysterols and (ii) remove excess derivatisation reagents. Re-
cent inter-batch variation in C18 reversed-phase cartridges has
led us to experiment with alternative columns. Here, we pres-
ent our findings and report an improved sample preparation
procedure using polymeric hydrophilic–lipophilic balanced
reversed-phase cartridges.
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MS Mass spectrometry
MSn Tandem mass spectrometry or mass
spectrometry with multistage
fragmentation
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Introduction
Oxysterols are oxidised forms of cholesterol incorporating
one or more hydroxyl, carbonyl, epoxide or carboxylic acid
group onto the cholesterol skeleton. Historically, oxysterols
have been known as intermediates in the biosynthesis of bile
acids and as important transport forms of cholesterol. Howev-
er, in recent years, interest in these compounds has grown as
they have been shown to have important signalling roles, for
example, as agonists to the liver X receptors (LXRs) and the G
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protein-coupled receptor Epstein-Barr virus-induced receptor
2 (EBI2, GPR183). Some studies have also shown potential
roles for oxysterols in the progression of neurodegenerative
diseases, the formation of atherosclerotic plaques and as bio-
markers for oxidative stress [1].
Biosynthesis of oxysterols from cholesterol is catalysed by
a number of sterol hydroxylases, often members of the cyto-
chrome P450 (CYP) family. For example, CYP7A1 converts
c ho l e s t e r o l t o cho l e s t - 5 - en e - 3β , 7α - d i o l ( 7α -
hydroxycholesterol, 7α-HC) in the first step of the neutral
pathway of bile acid biosynthesis. Similarly, CYP27A1 catal-
yses the formation of cholest-5-ene-3β,(25R)26-diol
((25R)26-hydroxycholesterol, 26-HC) in the first step of the
acidic pathway. Note, we use the systematic nomenclature
where addition of a hydroxyl group to the terminal carbon of
the cholesterol side-chain introducing R stereochemistry at
C-25 is said to be at C-26 [2].
The low levels of endogenous oxysterols (pg/mL to ng/mL
in human plasma) coupled with a lack of chromophore and
poor ionisation characteristics make analysis challenging [1].
Gas chromatography (GC)–mass spectrometry (MS) follow-
ing sample extraction, hydrolysis and derivatisation has long
been considered the ‘gold standard’ analytical method [3].
Recently, several liquid chromatography (LC)-MS methods
have been reported both with and without prior derivatisation
to improve ionisation [1, 4, 5].
In any method of oxysterol analysis products formed by
non-enzymatic autoxidation of cholesterol during sample stor-
age, handling and workup can complicate reliable identifica-
tion and quantification. Methods used to avoid artefacts de-
rived from cholesterol include the use of antioxidants such as
butylated hydroxytoluene (BHT), strict exclusion of atmo-
spheric oxygen using an inert gas such as argon and reducing
photo-induced oxidation by handling samples in the dark or in
low light. An alternative strategy, which we favour, relies on
prompt separation of cholesterol from oxysterols at the earliest
possible point of the sample workup using solid-phase extrac-
tion (SPE). After separation of oxysterols from cholesterol by
SPE-1, we carry out an enzymatic oxidation of the character-
istic oxysterol 3β-hydroxy-Δ-5 group to the corresponding 3-
oxo-Δ-4 moiety, followed by a ‘click-chemistry’ reaction with
the Girard P (GP) hydrazine reagent to introduce a permanently
charged quaternary ammonium group (see Electronic Supple-
mentary Material (ESM) Fig. S1). This greatly enhances signal
in electrospray ionisation (ESI), by a factor of about 102–103,
and improves solubility in reversed-phase solvents to aid LC
separation of oxysterols. In addition, the GP-derivatised sterols
give a characteristic fragmentation pattern upon tandem MS
(MSn) analysis. We have termed this method enzyme-assisted
derivatisation for sterol analysis (EADSA) [5].
After derivatisation, a second SPE step (i.e. SPE-2, ESM
Fig. S2) is necessary to remove excess reagent before analysis.
We have used a 200-mgWaters Sep-Pak tC18 reversed-phase
cartridge with a method optimised for the recovery of
oxysterols with a side-chain hydroxyl group (e.g. 22R-,
24S-, 25- and 26-HC) and for cholestenoic acids (e.g. 3β-
hydroxycholest-5-enoic acid and 3β,7α-dihydroxycholest-5-
enoic acid). However, recent experience has shown consider-
able batch-to-batch variation in the performance of this car-
tridge. Here, we describe our efforts to re-optimise our SPE




Absolute ethanol and HPLC grade solvents were from Fisher
Scientific (Loughborough, UK). Acetic acid was AnalaR
NORMAPUR grade (BDH, VWR, Lutterworth, UK) and
formic acid was from Sigma-Aldrich (Dorset, UK). Authentic
sterol standards were from Avanti Polar Lipids (Alabama,
USA) or Sigma-Aldrich. Cholesterol oxidase was from
Sigma-Aldrich and the GP reagent was from TCI Europe (Ox-
ford, UK). The plasma sample used was from Sigma-Aldrich.
Certified Sep-Pak tC18 200-mg cartridges and Oasis HLB 60-
mg cartridges were generously donated by Waters (Elstree,
UK). Telos C18 with and without endcapping (Kinesis),
Isolute C18 andHypersep C18 (ThermoFisher) were generous
gifts from the manufacturers.
Methods
The derivatisation and LC-MSn methods (ESM Fig. S1 and
S2) are described in detail in Griffiths et al. [5].
Results
Inter-batch variation in Waters Sep-Pak tC18 cartridges
When analysing a plasma sample as part of a recent study, we
observed very low intensity signals for a range of analytes
including our internal standard, 24R/S-[25,26,26,26,27,27,
27-2H7]hydroxycholesterol ([
2H7]24R/S-HC). To try and
identify the problem, we initially used a simple mixture of
synthetic standards to very approximately mimic the steroid
and sterol content of plasma. This was made up of 5 μg of
[2H7]24R/S-HC, cholest-4-en-3-one and dehydroepiandroster-
one sulphate (DHEAS). These compounds cover a wide range
of hydrophobicity and, therefore, have different profiles on
reversed-phase SPE and LC columns.
Firstly, the mixture of standards was subjected to our
established conditions for EADSA and analysed by LC-MSn
on the LTQ-Orbitrap Velos. However, as we were analysing a
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mixture of standards rather than biological samples, the remov-
al of cholesterol by SPE-1 was not deemed necessary. Only the
SPE-2 step for the removal of excess derivatisation reagent was
carried out. The inclusion of cholest-4-en-3-one was used to
control for any problems with the cholesterol oxidase step as
cholest-4-en-3-one does not require enzymatic oxidation before
derivatisation with the GP reagent. DHEAS is very polar and
when derivatisedwith the GP reagent elutes after about 1min in
our LC gradient, while cholest-4-en-3-one elutes after about
12 min. [2H7]24R/S-HC is our usual internal standard and is
representative of side-chain hydroxycholesterols, eluting from
the LC at about 8 min. Shown in Fig. 1 are reconstructed ion
chromatograms (RICs) for these standards recorded earlier un-
der optimal conditions. In our initial study, we replaced all
materials with new batches and we were able to rule out prob-
lems with solvent purity, reagent stability and enzyme activity
as the reason for low signal intensity. However, we observed a
marked difference between two batches of Sep-Pak tC18 200-
mg cartridges employed for SPE-2. Very poor recovery of
[2H7]24R/S-HC was observed when using a recent batch,
011133059D (batch D), compared to an older one,
011032331C (batch C) (ESM Figure S3a). Similarly, there
was no measurable recovery of cholest-4-en-3-one when batch
D was employed (ESM Figure S3b). However, the much less
hydrophobic DHEAS eluted well from both batches of car-
tridge (ESM Figure S3c). While the cause of this inter-batch
variation was not immediately clear, it is probable that a cation
exchange mechanism is also operating in the D-batch rather
than solely reversed-phase interactions as in the C-batch. While
GP-derivatised DHEAS in aqueous alcohol is zwitterionic but
electrically neutral, sterols and oxysterols are cationic and thus
retained by any cation exchange interactions on the D-batch of
SPE-2. Consistent with this hypothesis, we found that elution
with a more polar solvent (ethanol) had no effect on the out-
come of the experiment.
Other C18 cartridges
In an attempt to find an alternative cartridge suitable for our
SPE-2 step, we tested C18 columns fromBiotage, Kinesis and
ThermoFisher using our mixture of standards. We found that
the zwitterionic neutral analyte DHEAS elutedwell from all of
the cartridges with very little variation in the peak area (ESM
Figure S4a). However, [2H7]24R/S-HC only eluted satisfacto-
rily from the Sep-Pak tC18 column from batch C, with the
other sorbents retaining this analyte (ESMFig. S4b). Themost
hydrophobic compound, cholest-4-en-3-one, was not found to
elute from any cartridges other than Sep-Pak tC18 batch C
(ESM Fig. S4c). This data indicates that like Sep-Pak tC18
batch D, but in contrast to batch C, the other C18 columns
retain cationic GP-derivatised analytes.
Oasis HLB cartridges
As we were unable to obtain satisfactory results with any of
the C18 cartridges tested, other than Sep-Pak tC18 batch C,
which is no longer commercially available, we next turned our













































Fig. 1 Structures and representative chromatograms of synthetic
standards after derivatisation by EADSA. Retention times: DHEAS,
1.15 min; [2H7]24R/S-HC, 7.82 min; cholest-4-en-3-one, 11.99 min.
[2H7]24R/S-HC gives four peaks as each of the R and S isomers give
syn and anti conformers upon EADSA. SPE-2 was from batch C
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reversed-phase Oasis HLB column (ESM Fig. S5). The man-
ufacturer recommends using approximately one third of the
sorbent mass compared with an equivalent C18 cartridge. We
used the 60-mg Oasis HLB column (cf. 200-mg tC18 Sep-Pak
normally used for SPE-2) but maintained the same solvent
volumes. With this method, the recoveries using the Oasis
HLB cartridge of both DHEAS and [2H7]24R/S-HC were as
good as when using Sep-Pak tC18 batch C (ESM Fig. S6a and
S6b). Surprisingly, the most hydrophobic analyte (cholest-4-
en-3-one) gave about a 50-fold larger peak area when using
the polymeric cartridge compared to the C18 batch C (ESM
Fig. S6c), suggesting that the Oasis HLB sorbent may be
particularly useful for the recovery of hydrophobic analytes.
Testing with a biological sample
As the results from our mixture of standards were satisfactory,
we next tested the Oasis HLB cartridge using a commercially
available plasma sample. The first step of our protocol for
extraction of oxysterols from plasma requires the separation
of cholesterol from oxysterols by SPE-1 (ESM Fig. S2). Cho-
lesterol is present at levels of about 1000-fold higher than
endogenous oxysterols and can generate artefacts by non-
enzymatic autoxidation during sample preparation. We have
previously found that the Waters Sep-Pak tC18 removes
>99.9 % of the cholesterol present in biological samples gen-
erating the oxysterol fraction SPE-1-Fr-1. In this study, we
Fig. 2 Comparison of SPE cartridges for the removal of cholesterol.
Reconstructed ion chromatograms (RIC) for 518.4105±10 ppm. (a)
Waters Sep-Pak tC18 batch 011032331C, (b) Waters Sep-Pak tC18
batch 011133059D, and (c) Waters Oasis HLB. Cholesterol retention






Fig. 3 Comparison of SPE
cartridges for the recovery of side-
chain hydroxycholesterols after
EADSA. RICs for (a) m/z
541.4493±10 ppm showing
[2H7]24R/S-HC. Top panel SPE-2
is Waters Sep-Pak tC18 batch
011032331C; bottom panel SPE-
2 is Waters Oasis HLB and (b)
RIC for m/z 534.4054±10 ppm
showing endogenous side-chain
hydroxycholesterols. Top panel
SPE-2 is Waters Sep-Pak tC18
batch 011032331C; bottom panel
SPE-2 is Waters Oasis HLB.
Peaks in (a) and (b) are
normalised to the most intense
peak in each column
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found that both batches C and D of Sep-Pak tC18 worked well
to remove cholesterol (Fig. 2a, b) but Oasis HLB cartridges
were much less effective (Fig. 2c, cholesterol retention time
11.99). C18 cartridges from other manufacturers also worked
well for this step (data not shown).
To evaluate the Oasis HLB cartridge for SPE-2, the
oxysterol fraction obtained from a Sep-Pak tC18 cartridge
(batch C) was split into two identical samples. These were
oxidised with cholesterol oxidase and derivatised with the
GP reagent in parallel. To remove the excess reagent, we used
an Oasis HLB cartridge for one sample and a Sep-Pak tC18
(batch C) for the other. Analysis of the samples by LC-MSn
then allowed us to directly compare the two columns. As with
the mixture of standards, the two cartridges gave similar peak
areas for our internal standard, [2H7]24R/S-HC, with a slightly
higher signal when using the Oasis HLB sorbent (Fig. 3a). We
use this standard to quantify endogenous side-chain
hydroxycholesterols, i.e. 24S-HC, 25-HC and 26-HC. For the-
se analytes, the peak areas were similar for samples worked up
using either of the two cartridges for SPE-2 (Fig. 3b). As well
as side-chain hydroxycholesterols, we also analyse oxysterols
with the hydroxyl group on the B-ring, i.e. 7α-HC and 7β-HC.
For the quantification of these compounds, we add 7α-[25,26,
26,27,27,27-2H7]hydroxycholesterol ([
2H7]7α-HC) to our
samples as an internal standard. All of these analytes elute 2–
3 min after the side-chain hydroxycholesterols. For these com-
pounds, we observed peak areas approximately three times
larger when using the Oasis HLB cartridge compared with
the Sep-Pak tC18 cartridge as SPE-2 (ESM Fig. S7). For
oxysterols in plasma, we find an intra-batch CV of <15 %.
The inter-batch CV for OASIS cartridges is no larger than the
intra-batch CV.
Discussion
Having evaluated a number of SPE cartridges, we have now
optimised sample preparation procedure for EADSA. For the
separation of cholesterol from oxysterols in SPE-1, C18-based
sorbents are the most effective. We use Waters Certified Sep-
Pak tC18 columns for this step. This successfully removes
>99.9 % of the cholesterol from the oxysterol fraction, what-
ever batch is used, greatly reducing the risk of generating
artefacts by autoxidation. However, as the more recent batches
of Sep-Pak tC18 gave unsatisfactory results for the recovery
of charge-tagged sterols, we now use Waters Oasis HLB car-
tridges for SPE-2. In addition, the greater recovery of B-ring
hydroxycholesterols using this column is a distinct advantage
as it improves the sensitivity and reliability of the method.
Acknowledgments Work in Swansea was supported by the UK Bio-
technology and Biological Sciences Research Council (BBSRC, grant
numbers BB/I001735/1 to WJG, BB/L001942/1 to YW). We are grateful
to Eylan Yutuc and Jonas Abdel-Khalik for assistance in assay validation.
Members of the European Network for Oxysterol Research (ENOR,
http://oxysterols.com/) are thanked for informative discussions.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. GriffithsWJ, Crick PJ,WangY (2013)Methods for oxysterol analysis:
past, present and future. Biochem Pharmacol 86(1):3–14. doi:10.1016/
j.bcp.2013.01.027
2. Fakheri RJ, Javitt NB (2012) 27-Hydroxycholesterol, does it exist? On
the nomenclature and stereochemistry of 26-hydroxylated sterols.
Steroids 77(6):575–577. doi:10.1016/j.steroids.2012.02.006
3. Dzeletovic S, Breuer O, Lund E, Diczfalusy U (1995) Determination
of cholesterol oxidation-products in human plasma by isotope-dilution
mass-spectrometry. Anal Biochem 225(1):73–80. doi:10.1006/abio.
1995.1110
4. McDonald JG, Smith DD, Stiles AR, Russell DW (2012) A compre-
hensive method for extraction and quantitative analysis of sterols and
secosteroids from human plasma. J Lipid Res 53(7):1399–1409. doi:
10.1194/jlr.D022285
5. Griffiths WJ, Crick PJ, Wang Y, Ogundare M, Tuschl K, Morris AA,
Bigger BW, Clayton PT, Wang Y (2013) Analytical strategies for
characterization of oxysterol lipidomes: liver X receptor ligands in
plasma. Free Radic Biol Med 59:69–84. doi:10.1016/j .
freeradbiomed.2012.07.027
Revised sample preparation for the analysis of oxysterols 5239
